TP53 and non-small cell lung carcinoma: A recent study which contained 165 patients with KRAS-mutant NSCLC undergoing anti-PD-1/PD-L1 immunotherapy demonstrated that the co-mutation of TP53 might be associated with higher response (Lee et al. 2018).